---
title: "Brief News: Although there are improvements in the fourth quarter data, JXR's annual business still fell by 1.4%"
description: "JXR released data showing that the number of in vitro fertilization (IVF) treatments in the fourth quarter of 2025 was 7,004, an increase of 12% year-on-year. Despite a strong performance in the fourt"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271614532.md"
published_at: "2026-01-06T07:10:45.000Z"
---

# Brief News: Although there are improvements in the fourth quarter data, JXR's annual business still fell by 1.4%

> JXR released data showing that the number of in vitro fertilization (IVF) treatments in the fourth quarter of 2025 was 7,004, an increase of 12% year-on-year. Despite a strong performance in the fourth quarter, the total number of IVF treatments for the year still declined by 1.4% to 28,039. The IVF treatments at the Chengdu flagship center rose by 1.3% to 14,070, while overseas business fell by 6.9% to 4,235. On Tuesday, the stock price slightly increased to HKD 2.50, down about 5% over the past 52 weeks

According to data released by the fertility service provider **JXR** (1951.HK) on Monday, it provided 7,004 in vitro fertilization (IVF) treatments to clients in the fourth quarter of last year, a year-on-year increase of 12%. This strong growth reflects the company's business rebounding after a weak performance in early 2025.

After accounting for the strong fourth-quarter performance, the total number of IVF treatments for the entire year of 2025 decreased by 1.4% year-on-year to 28,039, an improvement compared to a 5.2% decline in the first nine months of last year.

The company's flagship center in Chengdu provided 14,070 IVF treatments in 2025, an increase of 1.3% year-on-year, accounting for about half of the total business volume. However, treatments provided by overseas operations decreased by 6.9% year-on-year to 4,235, as the company closed its IVF center in Laos, leaving only the United States for overseas operations.

JXR rose slightly to HKD 2.50 in early trading on Tuesday afternoon, with its stock price down about 5% over the past 52 weeks

### Related Stocks

- [01951.HK - JXR](https://longbridge.com/en/quote/01951.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 15:16 ETDr. Eric Haeger Scholarship for Future Doctors Announces National Opportunity Supporting Undergraduate Students Pursuing Careers in Medicine | The Dr. Eric Haeger Scholarship for Future Doctors is now accepting applications from undergraduate students pursuing ca | [Link](https://longbridge.com/en/news/275941229.md) |
| Dr. Andrew Gomes Grant for Medical Students Launches Prestigious Grant for Undergraduates to Advance Careers in Healthcare | The Dr. Andrew Gomes Grant for Medical Students has launched its 2026 application cycle, offering $1,000 to undergraduat | [Link](https://longbridge.com/en/news/275997328.md) |
| 12:31 ETTallahassee Memorial HealthCare Advances Cath Lab Safety through First-in-the-World Technology Adoption | Tallahassee Memorial HealthCare (TMH) has made history by becoming the first hospital globally to implement AeroShield™, | [Link](https://longbridge.com/en/news/275494850.md) |
| ZAWYA-PRESSR: Almond Blossoms Fertility & Wellbeing Center launches in Dubai | Almond Blossoms Fertility & Wellbeing Center has opened in Dubai Healthcare City, offering an integrated approach to fer | [Link](https://longbridge.com/en/news/275635016.md) |
| Avanti Capital Advances Impact-Driven Investing and Expands Commitment to Philanthropy | Avanti Capital, a multi-generational family office, is enhancing its impact-driven investing across various sectors, inc | [Link](https://longbridge.com/en/news/275701455.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.